Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.

Abstract: A double-wall pipe for a transportation means which includes an outer pipe and an inner pipe extending therein. The outer pipe has two pipe segments which are formed like half-shells and are joined together to form the outer pipe along the longitudinal edges thereof. In this way, it is possible to make both the outer pipe and the inner pipe of metal, such that the wall thickness of the inner pipe can be relatively small.

Abstract: Providing a reward as an incentive for a person to become an audience member of at least one program being performed by reproduction equipment. A programming signal used for broadcasting the program with a programming signal source is encoded with discrete code signals, such that a preset number of the code signals occur within a given period of time, to produce an output signal which is broadcast. The broadcast output signal is received, and the code signals therein are detected. The number of the code signals detected while the person is an audience member of the at least one program is compared with predetermined reward issuance criteria. A reward is issued when the reward issuance criteria are met by the number of detected code signals.

Abstract: The invention refers to methods for detecting and/or quantifying the interaction of platelets or platelet surface molecules with an interaction partner, methods for detecting and/or quantifying the capability of a test substance to modulate the interaction of platelets or platelet surface molecules with interaction partners and articles or manufacture.

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion pheno-type. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: The invention relates to a node device (21) for a network (20) comprising quantum cryptographic connections (1) provided with quantum channels (4) and public channels (5), comprising quantum optics means (11) for connecting to the respective quantum channels, for generating secrets or keys by means of quantum cryptography, comprising means (13) for managing symmetrical secrets or keys, cryptography means (14) for generating cryptograms, and driver means (15) connected thereto for transmission via a public channel, wherein the means (15) for managing symmetrical secrets or keys and the cryptography and driver means (14; 15) are combined in a common node module (24) as central components (13, 14, 15) for a plurality of quantum channel connections, while the quantum optics means (11) are provided separately in decentral modules (23) for the plurality of quantum channel connections.

Abstract: The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.

Abstract: An interactive technique for generating a supplementary, program-related output. A programming signal and a supplementary, program-related data signal are combined into a broadcast signal which is then broadcast from a program signal source. The broadcast signal is received, and the programming signal of the received broadcast signal is performed with reproduction equipment for an audience. The supplementary, program-related data signal of the received broadcast signal is stored, and retrieval of the stored supplementary, program-related data signal is enabled interactively with the programming signal being performed. In response to a control signal being actuated by a member of the audience tuned to the programming signal being performed, the stored supplementary, program-related data signal is retrieved and used to generate the supplementary, program-related output.

Abstract: The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention.

Abstract: The invention relates to a node device (21) for a network (20) comprising quantum cryptographic connections (1) provided with quantum channels (4) and public channels (5), comprising quantum optics means (11) for connecting to the respective quantum channels, for generating secrets or keys by means of quantum cryptography, comprising means (13) for managing symmetrical secrets or keys, cryptography means (14) for generating cryptograms, and driver means (15) connected thereto for transmission via a public channel, wherein the means (15) for managing symmetrical secrets or keys and the cryptography and driver means (14; 15) are combined in a common node module (24) as central components (13, 14, 15) for a plurality of quantum channel connections, while the quantum optics means (11) are provided separately in decentral modules (23) for the plurality of quantum channel connections.

Abstract: An interactive technique for generating a supplementary, program-related output. A programming signal and a supplementary, program-related data signal are combined into a broadcast signal which is then broadcast from a program signal source. The broadcast signal is received, and the programming signal of the received broadcast signal is performed with reproduction equipment for an audience. The supplementary, program-related data signal of the received broadcast signal is stored, and retrieval of the stored supplementary, program-related data signal is enabled interactively with the programming signal being performed. In response to a control signal being actuated by a member of the audience tuned to the programming signal being performed, the stored supplementary, program-related data signal is retrieved and used to generate the supplementary, program-related output.

Abstract: An audience surveying technique for identifying individual members of an audience listening to and/or watching a program performed from a programming signal source. A stationary apparatus is operatively arranged at a reception location with a plurality of portable devices designed to be worn by the audience members. The stationary apparatus detects and stores a surveying code transmitted with the program, and it also periodically emits a trigger signal which causes the portable devices to respond by emitting a unique identification signal pre-stored in each one. The stationary apparatus also detects and stores the identification signals. By associating the detected surveying code with the detected identification signals it is possible to quickly, accurately and reliably identify the individual audience members tuned to a particular program.